-- 
Mazor Gains Most in 4 Months on FDA, CE Approval of System

-- B y   S h a r o n   W r o b e l
-- 
2011-06-06T13:47:07Z

-- http://www.bloomberg.com/news/2011-06-06/mazor-gains-most-in-4-months-on-fda-ce-approval-of-system-1-.html
Mazor Robotics Ltd. (MZOR)  rose the most in
more than four months after the developer of surgical robots got
European CE and the U.S. Food and Drug Administration approval
for the marketing of its Renaissance system.  The shares climbed 5.5 percent to 8.502 shekels at the 4:30
p.m. close in  Tel Aviv , the largest increase since Jan. 25.  Renaissance will replace its SpineAssist system used for
surgery, the company said. The system will be marketed in the
U.S., Europe and Asia and is expected to generate sales in the
fourth quarter.  To contact the reporter on this story:
Sharon Wrobel in Tel Aviv at 
 swrobel4@bloomberg.net   To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  